Literature DB >> 20218473

Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment.

K G P Hoek1, H S Schaaf, N C Gey van Pittius, P D van Helden, R M Warren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20218473

Source DB:  PubMed          Journal:  S Afr Med J


× No keyword cloud information.
  8 in total

1.  False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications.

Authors:  A Van Rie; K Mellet; M-A John; L Scott; L Page-Shipp; H Dansey; T Victor; R Warren
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

2.  Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa.

Authors:  Violet N Chihota; Borna Müller; Charmaine K Mlambo; Manormoney Pillay; Marisa Tait; Elizabeth M Streicher; Else Marais; Gian D van der Spuy; Madeleine Hanekom; Gerrit Coetzee; Andre Trollip; Cindy Hayes; Marlein E Bosman; Nico C Gey van Pittius; Tommie C Victor; Paul D van Helden; Robin M Warren
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

3.  Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia.

Authors:  Kedir Abdella; Ketema Abdissa; Wakjira Kebede; Gemeda Abebe
Journal:  BMC Public Health       Date:  2015-07-02       Impact factor: 3.295

4.  Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa.

Authors:  Borna Müller; Violet N Chihota; Manormoney Pillay; Marisa Klopper; Elizabeth M Streicher; Gerrit Coetzee; Andre Trollip; Cindy Hayes; Marlein E Bosman; Nicolaas C Gey van Pittius; Thomas C Victor; Sebastien Gagneux; Paul D van Helden; Robin M Warren
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

5.  Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades.

Authors:  Arnold Bainomugisa; Evelyn Lavu; Stenard Hiashiri; Suman Majumdar; Alice Honjepari; Rendi Moke; Paison Dakulala; Grant A Hill-Cawthorne; Sushil Pandey; Ben J Marais; Chris Coulter; Lachlan Coin
Journal:  Microb Genom       Date:  2018-01-04

6.  Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).

Authors:  James A Seddon; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Anne-Marie Demers; Graeme Hoddinott; Angela M Crook; Ellen Owen-Powell; Margaret J Thomason; Anna Turkova; Diana M Gibb; Lee Fairlie; Neil Martinson; H Simon Schaaf; Anneke C Hesseling
Journal:  Trials       Date:  2018-12-20       Impact factor: 2.279

7.  Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.

Authors:  Eyob Abera Mesfin; Dereje Beyene; Abreham Tesfaye; Addisu Admasu; Desalegn Addise; Miskir Amare; Biniyam Dagne; Zelalem Yaregal; Ephrem Tesfaye; Belay Tessema
Journal:  PLoS One       Date:  2018-06-04       Impact factor: 3.240

8.  Key Issues in the Management of Multi-Drug Resistant Tuberculosis: A Case Report.

Authors:  Zorica Nanovic; Biserka Kaeva-Jovkovska; Gorica Breskovska; Milena Petrovska
Journal:  Open Access Maced J Med Sci       Date:  2018-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.